NEW YORK (GenomeWeb) – Horizon Discovery announced today that it has entered an agreement with Roche Diagnostics to develop immunohistochemistry reference standards for oncology assays.

The company will develop and provide reference standard material for neurotrophic tropomyosin receptor kinase (NTRK) fusion biomarkers. Effective use of compounds against fusion proteins resulting from NTRK gene rearrangements depends on accurate genotyping of patients, Horizon noted in a statement, and this is typically done using immunohistochemistry.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.